Lido Advisors
CORT icon

Lido Advisors’s Corcept Therapeutics CORT Stock Holding History

Lido Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$739K Buy
+8,499
New +$513K ﹤0.01% 1260
2025
Q3 		– Sell
-6,064
Closed -$445K – 1851
2025
Q2 		$445K Buy
6,064
+463
+8% +$33.6K ﹤0.01% 1150
2025
Q1 		$640K Buy
+5,601
New +$341K ﹤0.01% 936
2023
Q3 		– Sell
-16,199
Closed -$360K – 1241
2023
Q2 		$360K Sell
16,199
-6,809
-30% -$157K ﹤0.01% 848
2023
Q1 		$498K Buy
+23,008
New +$504K ﹤0.01% 666

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's CORT Position: Q2 2026 in Review

Lido Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 8,499 shares worth $739K. The stake represents ﹤0.01% of the portfolio and ranks #1260 among its holdings. This is a return to the name: Lido Advisors previously reported a position in CORT as recently as Q2 2025.

Lido Advisors first reported a position in CORT in Q1 2023 and has held it in 5 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Lido Advisors held 8,499 shares of Corcept Therapeutics worth $739K as of Q2 2026.
  • Corcept Therapeutics was a new Lido Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1260 holding.
  • Lido Advisors first reported a position in Corcept Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.